The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade.
 
Veronique Debien
No Relationships to Disclose
 
Virginie ADAM
Research Funding - AstraZeneca Japan (Inst); Biovica (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst)
Patents, Royalties, Other Intellectual Property - Agendia (Inst)
 
Rafael Caparica
Employment - Novartis
 
Debora Fumagalli
Research Funding - AstraZeneca (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst); Tesaro (Inst)
 
Chloé Velghe
No Relationships to Disclose
 
Julie Gaye
No Relationships to Disclose
 
Vanessa Correia De Nobrega
Research Funding - AstraZeneca Japan (Inst); Biovica (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst)
Patents, Royalties, Other Intellectual Property - Agendia (Inst)
 
Amal Arahmani
Research Funding - AstraZeneca (Inst); BIOVICA (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); SANOFI (Inst); SERVIER (Inst); TESARO (Inst)
Patents, Royalties, Other Intellectual Property - Agendia (Inst)
 
Gabriele Zoppoli
Research Funding - Thermo Fisher Scientific (Inst)
Patents, Royalties, Other Intellectual Property - AstraZeneca UK concerning methods for SLFN11 detection in cancer samples and its correlation with clinical outcome; Davide Bedognetti and Wouter Hendricxk from SIDRA Medicine, Doha, concerning in vitro experiments with SLFN11 and cancer models; European patent no. 102019000018989 concerning a "multi-domain method for prediction of one-year mortality in senior patients diagnosed with cancer"
Travel, Accommodations, Expenses - Novartis; Roche
(OPTIONAL) Uncompensated Relationships - AstraZeneca; Breast International Group; Breast International Group/International Breast Cancer Study Group; European Organisation for Research and Treatment of Cancer (EORTC); Roche
 
Martine J. Piccart-Gebhart
Consulting or Advisory Role - AstraZeneca; Camel-IDS; Frame Therapeutics; Immunomedics; Immutep; Lilly; Menarini; MSD; NBE Therapeutics; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen; Seagen
Research Funding - AstraZeneca (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Roche/Genentech (Inst); Servier (Inst); Synthon (Inst)
Other Relationship - EU Cancer Mission Board; Oncolytics